Literature DB >> 12169887

Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature.

Julien Zuber1, Frank Martinez, Dominique Droz, Eric Oksenhendler, Chirstophe Legendre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169887     DOI: 10.1097/00005792-200207000-00008

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


× No keyword cloud information.
  11 in total

Review 1.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.

Authors:  Mark A Perazella; Anushree C Shirali
Journal:  J Am Soc Nephrol       Date:  2018-06-29       Impact factor: 10.121

Review 2.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

3.  Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.

Authors:  Corentin Orvain; Jean-François Augusto; Virginie Besson; Guillaume Marc; Paul Coppo; Jean-François Subra; Johnny Sayegh
Journal:  Int Urol Nephrol       Date:  2013-02-24       Impact factor: 2.370

Review 4.  Drug-induced glomerular disease: direct cellular injury.

Authors:  Glen S Markowitz; Andrew S Bomback; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-10       Impact factor: 8.237

5.  Late mortality from thrombotic microangiopathy after liver transplantation: report of a case.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Sumihito Tamura; Junichi Togashi; Junichi Kaneko; Masatoshi Makuuchi
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

6.  A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.

Authors:  Chiaki Okuse; Kayo Adachi; Yoshiki Katakura; Kotaro Matsunaga; Toshiya Ishii; Nobuyuki Matsumoto; Hiroshi Yotsuyanagi; Shiro Iino; Michihiro Suzuki; Fumio Itoh
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

7.  Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Authors:  David Kavanagh; Sarah McGlasson; Alexa Jury; Jac Williams; Neil Scolding; Chris Bellamy; Claudia Gunther; Diane Ritchie; Daniel P Gale; Yashpal S Kanwar; Rachel Challis; Holly Buist; James Overell; Belinda Weller; Oliver Flossmann; Mark Blunden; Eric P Meyer; Thomas Krucker; Stephen J W Evans; Iain L Campbell; Andrew P Jackson; Siddharthan Chandran; David P J Hunt
Journal:  Blood       Date:  2016-09-23       Impact factor: 25.476

8.  Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.

Authors:  Julien Mahe; Aurélie Meurette; Anne Moreau; Caroline Vercel; Pascale Jolliet
Journal:  Drug Des Devel Ther       Date:  2013-08-07       Impact factor: 4.162

9.  Thrombotic Microangiopathy in Interferon-beta-Treated Multiple Sclerosis Patient.

Authors:  Masoud Mohammad Malekzadeh; Reza Alizadeh; Ziba Aghsaeifard; Mohammad Ali Sahraian
Journal:  Clin Case Rep       Date:  2020-03-30

Review 10.  Side effects of cytokines approved for therapy.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.